Epinephrine

Gov. Phil Murphy of New Jersey has signed legislation that will cap monthly out-of-pocket prescription costs for epinephrine autoinjectors at $25 and asthma inhalers at $50 in all state-regulated and public employee health insurance plans.

Healio compiled the most-read news in allergy, asthma and immunology posted in June.

The FDA has set a new target action date for ARS Pharmaceuticals’ neffy epinephrine nasal spray, which is designed to treat anaphylaxis and other type 1 allergic reactions without a needle or injection.

The FDA has extended the prescription drug user fee act target action date for the new drug application for neffy intranasal epinephrine spray from ARS Pharmaceuticals to Sept. 19, according to a company press release.

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

An FDA advisory committee voted in support of ARS Pharmaceuticals’ neffy nasal spray for anaphylaxis in adults and children, saying available data on the epinephrine spray indicate a favorable benefit-risk assessment.

The U.S. FDA Pulmonary-Allergy Drug Advisory Committee said available data support a favorable benefit-risk assessment for ARS Pharmaceuticals’ neffy nasal spray in treating anaphylaxis in adults and in children who weigh at least 30 kg.

A law moving through California’s legislature would require schools to store epinephrine autoinjectors in accessible locations and broadly share where those are, enabling prompt responses when children have anaphylactic reactions.

Severe reactions during home oral immunotherapy were rare, and milk OIT, asthma and sensitization to house dust mite were the main risk factors, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

When a child has an anaphylactic reaction in school, prompt administration of epinephrine can be lifesaving. Yet autoinjectors often are kept under lock and key in the nurse’s office, and school personnel lack the training to use them.